Device Debuts: Spinal Innovation From NuVasive, Life Spine; Teleflex Targets EuroPCR For Arrow AC3 Optimus; Abiomed Pushes 3-G Impella
Executive Summary
This edition of Device Debuts covers the innovative devices introduced into commercial markets since the mid-April, typically a busy time for product launches as it coincides with spring's big medical meetings. This includes a series of spine-surgery technologies showcased at the AANS meeting and devices that support blood circulation during interventions that were featured at EuroPCR and SCAI.
You may also be interested in...
Teleflex Buys Vascular Solutions For $1bn To Improve Growth
The purchase price of $56 a share in cash is a modest 16% premium over Vascular Solutions' 90-day average price. Vascular Solutions' CEO says uncertainty about the future leadership of the company compelled it to consider acquisition offers.
US FDA Approves Abiomed’s Impella For Cardiogenic Shock Ahead Of Schedule
US FDA has approved earlier than anticipated Abiomed’s Impella 2.5, Impella CP, Impella 5.0 and Impella LD transcatheter ventricular assist devices to provide treatment of ongoing cardiogenic shock.
Podcast Special: J&J's Andrie Leday Addresses ASC Market With Customized Approach
In this special podcast from Medtech Insight, editor Reed Miller talked to Andrie Leday, the US vice president for ambulatory surgery centers (ASCs) at Johnson & Johnson/DePuy Synthes. Leday's group is dedicated to creating a new "ecosystem" around DePuy Synthes broad range of orthopedic implants and tools to meet the demand of an aging population.